Takeover targets, notable drug launches, and more

What can we expect out of this biotech year? That's what everyone will be talking about next week at the annual J.P. Morgan Healthcare Conference in San Francisco. But why wait? STAT’s Adam Feuerstein gives us his take — projecting even more M&A activity in an already merge-happy sector, among other things. 

Also on the horizon: drug launches that could net big bucks for their makers — including the first-ever NASH drug, made by Intercept Pharmaceuticals. Cell therapies may undergo a shift of fundamentals, with allogenic therapies potentially making it into the limelight. 

Read more.